Françoise Jeanne Gellibert

Title: Françoise Jeanne Gellibert: Innovator in Pharmaceutical Chemistry

Introduction

Françoise Jeanne Gellibert is a notable inventor based in Les Ulis, France. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds with therapeutic applications. With a total of three patents to his name, Gellibert's work has had a meaningful impact on drug development.

Latest Patents

Gellibert's latest patents include the development of 1,2,4-oxadiazole derivatives as hPPAR alpha agonists. This patent describes a compound of formula (I) and pharmaceutically acceptable salts, solvates, and hydrolysable esters. The compound features specific structural elements, including variations in the elements X, Y, Z, R, and n, which contribute to its biological activity. Another significant patent involves carboline derivatives as PDE5 inhibitors. These selective inhibitors target cGMP-specific PDE and are disclosed for their potential use as therapeutic agents.

Career Highlights

Throughout his career, Gellibert has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Lilly Icos LLC and SmithKline Beecham Corporation. His work in these organizations has allowed him to contribute to the advancement of innovative therapeutic solutions.

Collaborations

Gellibert has collaborated with several professionals in his field, including Mark W. Orme and Jason Scott Sawyer. These collaborations have likely enriched his research and development efforts, leading to the successful creation of his patented compounds.

Conclusion

Françoise Jeanne Gellibert is a distinguished inventor whose work in pharmaceutical chemistry has led to the development of important therapeutic compounds. His contributions continue to influence the field and pave the way for future innovations.